PIPELINE
THERAPEUTIC FOCUS
AtlasMedx, Inc is focused on discovering and developing innovative and transformational small molecule drugs to treat and conquer cancer.
TECHNOLOGY
AtlasMedx therapeutic strategy consists of a platform of breakthrough synthetically lethal anti-cancer medicines that simultaneously target compensatory DNA repair, cell division, and migration mechanisms to selectively kill cancer cells and overcome resistance to chemotherapy while protecting healthy cells.
AMXI-5001 is the first effective, orally bioavailable agent designed to simultaneously inhibit microtubule polymerization and PARP within a single small molecule. It delivers continuous, steady-state dual-target inhibition that cannot be achieved with any IV microtubule-targeting agent (MTA) or MTA + PARP inhibitor combination.
• Oral colchicine-site microtubule inhibitor with low neuropathy risk
• Built-in PARP inhibition to block resistance pathways
• Continuous exposure without IV-associated Cmax or infusion-related toxicity
• Enables true synthetic-lethal synergy
AMXI-5001 is advancing through clinical development to unlock a safer, more effective treatment option across a broad range of cancers.